Boule Diagnostics AB AI Stock Analysis
Want to see SE:BOUL full AI Analyst Report?
Boule Diagnostics AB (BOUL) AI Stock Analysis
Boule Diagnostics AB
(Nasdaq OMX AB:BOUL)
The overall score is weighed down primarily by declining revenue, continued losses, weak margins, negative returns, and elevated leverage. Positive free cash flow offers limited support, while bearish technical momentum and the negative P/E ratio further constrain the score.
Boule Diagnostics AB (BOUL) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 53.98M
- Dividend Yield
- ―
- Average Volume (3M)
- 314.32K
- Price to Earnings (P/E)
- -3.1
- Beta (1Y)
- 0.83
- Revenue Growth
- -16.09%
- EPS Growth
- 78.68%
- Country
- Sweden
- Employees
- 200
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Specialties
Boule Diagnostics AB Business Overview & Revenue Model
Company Description
Boule Diagnostics AB (publ) develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East. The company p...
How the Company Makes Money
Boule Diagnostics makes money primarily by selling hematology instruments (analyzers) and by generating recurring revenue from consumables and related products used with those instruments. A typical model in hematology includes (1) upfront revenue fr...
Boule Diagnostics AB Financial Statement Overview
Summary
Financial performance is weak overall: revenue declined 6.7% TTM after a 12.3% decline in 2025, the company reported a net loss of 17.2 million, margins remain thin, and leverage is elevated. Positive operating and free cash flow provide some support, but the overall profile remains below average.
Income Statement
25NegativeBalance Sheet
45NeutralCash Flow
50Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 430.20M | 489.70M | 558.60M | 571.33M | 548.09M | 463.34M |
| Gross Profit | 185.30M | 213.80M | 252.40M | 249.71M | 227.91M | 198.63M |
| EBITDA | 14.20M | 23.12M | -255.90M | 65.98M | 57.84M | 55.69M |
| Net Income | -17.20M | -3.80M | -223.30M | 24.98M | 12.73M | 23.27M |
Balance Sheet | ||||||
| Total Assets | 463.50M | 469.60M | 590.20M | 755.11M | 759.96M | 572.03M |
| Cash, Cash Equivalents and Short-Term Investments | 13.50M | 19.60M | 22.70M | 37.28M | 96.90M | 38.18M |
| Total Debt | 216.50M | 223.76M | 195.00M | 166.17M | 189.97M | 155.44M |
| Total Liabilities | 298.60M | 301.90M | 320.60M | 280.01M | 297.46M | 276.30M |
| Stockholders Equity | 164.70M | 167.60M | 269.60M | 475.10M | 462.50M | 295.74M |
Cash Flow | ||||||
| Free Cash Flow | 21.00M | -4.13M | -39.30M | -31.30M | -86.31M | -13.09M |
| Operating Cash Flow | 26.90M | 829.00K | 46.60M | 51.38M | -11.35M | 43.28M |
| Investing Cash Flow | -6.50M | -5.00M | -85.90M | -82.71M | -74.96M | -56.37M |
| Financing Cash Flow | -27.50M | 3.30M | 24.40M | -25.51M | 140.55M | 15.75M |
Boule Diagnostics AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BOUL, the sentiment is Neutral. The current price of 1.39 is above the 20-day moving average (MA) of 1.38, below the 50-day MA of 2.05, and below the 200-day MA of 3.33, indicating a neutral trend. The MACD of -0.25 indicates Negative momentum. The RSI at 43.90 is Neutral, neither overbought nor oversold. The STOCH value of 56.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:BOUL.
Boule Diagnostics AB Peers Comparison
Overall Rating
- SE:BOUL38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| SE:BOUL | 38Underperform | SEK 48.35M | -3.10 | -58.52% | ― | -16.09% | 78.68% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:BOUL | Boule Diagnostics AB | 1.39 | -4.13 | -74.82% |
Boule Diagnostics AB Corporate Events
Boule Diagnostics Exits Instrument Business to Focus on Consumables and OEM
Boule Diagnostics is a global specialist in hematology diagnostics, supplying instruments, reagents, controls, spare parts and technical support through a broad international distributor network. Its OEM CDS business provides contract development and...
Boule Diagnostics Announces Fully Secured SEK 93 Million Rights Issue
Boule Diagnostics is a global hematology diagnostics specialist with more than 70 years of experience. Its market focus includes diagnostic instruments and a growing emphasis on consumables, service and original equipment manufacturer offerings, supp...
Boule Diagnostics Hit by Instrument Shortfall but Recurring Revenues Hold Margins
Boule Diagnostics AB reported a weak third quarter, as group net sales fell 24.4 percent to SEK 96.2 million due to a sharp 56.5 percent drop in instrument volumes, driven by component shortages and subdued demand in several markets. While these disr...
Boule Diagnostics Deepens Strategic Partnership to Drive Growth in Indian Diagnostics Market
Boule Diagnostics AB has updated its licensing agreement with long-time partner Q-Line Biotech Limited covering diagnostic reagents, consumables, and hematology analyzers in India, streamlining the commercial structure and aligning growth incentives....
Boule Diagnostics Secures Shareholder Loan at Extraordinary Meeting
Boule Diagnostics AB, a global provider of near‑patient human and veterinary diagnostic instruments, reagents, and controls, operates through its Diagnostics and OEM CDS segments. The company serves healthcare providers and diagnostic manufacturers a...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 06, 2026